Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
Obtaining improvements to the postnatal skin phenotype of DMKN α/β/γ deficient mice which are considered to be animal models of atopic dermatitis and ichthyosis from the embryonic to neonatal periods by administering therapeutics, proteins, cells, etc. are continuing to be researched. Currently, whether or not improvement of skin symptoms could be obtained by subcutaneously administering keratinocyte cells that express DMKN proteins was inspected. The subcutaneous administration to fetuses and newborn mice suggests that the skin phenotype at the administration site was improved. It is thought that this procedure could link to the treatment of newborn human fetuses with skin diseases.
|